Cogent Biosciences Key Executives
This section highlights Cogent Biosciences's key executives, including their titles and compensation details.
Find Contacts at Cogent Biosciences
(Showing 0 of )
Cogent Biosciences Earnings
This section highlights Cogent Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
$6.61
Stock Price
$752.55M
Market Cap
205
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Cogent Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $7.87M |
| Cost of Revenue | $- | $3.59M | $5.88M | $147.00K | $25.74K |
| Gross Profit | $- | $-3.59M | $-5.88M | $-147.00K | $7.85M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 99.67% |
| Research and Development Expenses | $232.66M | $170.17M | $121.63M | $55.91M | $72.65M |
| General and Administrative Expenses | $43.28M | $34.38M | $26.21M | $19.64M | $17.42M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $43.28M | $34.38M | $26.21M | $19.64M | $17.42M |
| Other Expenses | $- | $- | $3.61M | $2.81M | $-246.00K |
| Operating Expenses | $275.94M | $208.13M | $147.84M | $75.55M | $90.07M |
| Cost and Expenses | $275.94M | $208.13M | $147.84M | $75.55M | $90.07M |
| Interest Income | $18.09M | $13.08M | $3.99M | $467.00K | $144.00K |
| Interest Expense | $- | $- | $3.99M | $- | $- |
| Depreciation and Amortization | $- | $2.27M | $5.88M | $147.00K | $720.00K |
| EBITDA | $-275.94M | $-205.86M | $-134.36M | $-75.40M | $-34.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1139.52% |
| Operating Income | $-275.94M | $-208.13M | $-147.84M | $-75.55M | $-82.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1044.33% |
| Total Other Income Expenses Net | $20.08M | $15.72M | $7.60M | $3.28M | $7.39M |
| Income Before Tax | $-255.86M | $-192.41M | $-140.24M | $-72.27M | $-74.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -950.43% |
| Income Tax Expense | $- | $- | $-7.60M | $-467.00K | $-8.36M |
| Net Income | $-255.86M | $-192.41M | $-132.64M | $-71.81M | $-66.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -844.25% |
| EPS | $-3.49 | $-2.42 | $-2.26 | $-1.85 | $-6.00 |
| EPS Diluted | $-3.49 | $-2.42 | $-2.26 | $-1.85 | $-6.00 |
| Weighted Average Shares Outstanding | 73.35M | 79.66M | 58.74M | 38.73M | 11.08M |
| Weighted Average Shares Outstanding Diluted | 73.35M | 79.66M | 58.74M | 38.73M | 11.08M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $5.59M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $312.00K | $528.00K | $7.03M |
| Cost of Revenue | $- | $- | $1.08M | $1.07M | $794.00K | $855.00K | $1.22M | $723.00K | $937.00K | $3.71M | $97.00K | $69.00K | $68.00K | $48.00K | $14.00K | $17.00K | $6.11M | $5.00M | $5.13M | $9.50M |
| Gross Profit | $- | $- | $-1.08M | $-1.07M | $4.79M | $-855.00K | $-1.22M | $-723.00K | $-937.00K | $-3.71M | $-97.00K | $-69.00K | $-68.00K | $-48.00K | $-14.00K | $-17.00K | $-6.11M | $-4.69M | $-4.60M | $-2.47M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 85.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -77601321305960.22% | -1503.53% | -871.40% | -35.09% |
| Research and Development Expenses | $62.05M | $63.61M | $54.29M | $52.70M | $48.72M | $50.13M | $38.87M | $36.04M | $36.74M | $29.94M | $29.48M | $25.47M | $20.51M | $14.80M | $12.39M | $8.21M | $6.11M | $51.91M | $5.13M | $9.50M |
| General and Administrative Expenses | $11.69M | $11.80M | $10.09M | $9.70M | $9.51M | $9.45M | $8.21M | $7.20M | $7.00M | $6.88M | $6.38M | $5.95M | $5.13M | $5.02M | $4.90M | $4.59M | $5.35M | $5.60M | $2.80M | $3.67M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $11.69M | $11.80M | $10.09M | $9.70M | $9.51M | $9.45M | $8.21M | $7.20M | $7.00M | $6.88M | $6.38M | $5.95M | $5.13M | $5.02M | $4.90M | $4.59M | $5.35M | $5.60M | $2.80M | $3.67M |
| Other Expenses | $- | $- | $- | $-1.00K | $-7.00K | $- | $268.00K | $2.38M | $2.02M | $259.00K | $656.00K | $677.00K | $621.00K | $620.00K | $623.00K | $947.00K | $15.00K | $-270.00K | $7.00K | $- |
| Operating Expenses | $73.73M | $75.41M | $64.39M | $62.40M | $58.23M | $59.58M | $47.09M | $43.24M | $43.74M | $36.82M | $35.85M | $31.42M | $25.64M | $19.82M | $17.29M | $12.80M | $11.46M | $57.51M | $7.93M | $13.17M |
| Cost and Expenses | $73.73M | $75.41M | $64.39M | $62.40M | $58.23M | $59.58M | $47.09M | $43.24M | $43.74M | $36.82M | $35.85M | $31.42M | $25.64M | $19.82M | $17.29M | $12.80M | $11.46M | $57.51M | $7.93M | $13.17M |
| Interest Income | $3.86M | $4.78M | $5.39M | $4.06M | $3.87M | $4.20M | $2.74M | $2.27M | $2.11M | $1.50M | $272.00K | $107.00K | $107.00K | $115.00K | $120.00K | $125.00K | $70.00K | $23.00K | $3.00K | $47.00K |
| Interest Expense | $- | $- | $- | $- | $4.65M | $- | $- | $- | $2.11M | $1.50M | $- | $107.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.11M | $1.10M | $1.08M | $1.07M | $794.00K | $855.00K | $1.22M | $723.00K | $937.00K | $3.71M | $97.00K | $69.00K | $68.00K | $48.00K | $14.00K | $17.00K | $17.00K | $122.00K | $286.00K | $295.00K |
| EBITDA | $-72.63M | $-74.32M | $-63.31M | $-61.80M | $-57.63M | $-59.00M | $-46.52M | $-42.71M | $-43.33M | $-31.35M | $-35.76M | $-31.35M | $-25.57M | $-19.77M | $-17.28M | $-12.78M | $-11.44M | $-10.17M | $-7.12M | $-5.85M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1027.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -145928090458645.62% | -20725.00% | -1347.92% | -83.15% |
| Operating Income | $-73.73M | $-75.41M | $-64.39M | $-62.40M | $-58.23M | $-59.58M | $-47.09M | $-43.24M | $-43.74M | $-36.82M | $-35.85M | $-31.42M | $-25.64M | $-19.82M | $-17.29M | $-12.80M | $-11.46M | $-57.20M | $-7.40M | $-6.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1042.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -145534239613772.03% | -18333.01% | -1402.08% | -87.34% |
| Total Other Income Expenses Net | $5.81M | $4.78M | $5.44M | $4.06M | $3.86M | $4.20M | $3.01M | $4.65M | $4.13M | $1.76M | $928.00K | $784.00K | $728.00K | $735.00K | $743.00K | $1.07M | $118.00K | $7.22M | $10.00K | $47.00K |
| Income Before Tax | $-67.93M | $-70.63M | $-58.95M | $-58.35M | $-54.37M | $-55.38M | $-44.08M | $-38.59M | $-39.62M | $-35.06M | $-34.93M | $-30.63M | $-24.91M | $-19.08M | $-16.55M | $-11.73M | $-11.34M | $-49.98M | $-7.39M | $-6.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -972.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -144060475161987.00% | -16020.19% | -1400.19% | -86.67% |
| Income Tax Expense | $- | $- | $- | $-4.06M | $-3.87M | $-855.00K | $-3.96M | $-4.65M | $-4.13M | $-1.76M | $-1.43M | $-784.00K | $-728.00K | $-115.00K | $-120.00K | $-125.00K | $-118.00K | $-7.61M | $-3.00K | $- |
| Net Income | $-67.93M | $-70.63M | $-58.95M | $-58.35M | $-54.37M | $-55.38M | $-44.08M | $-33.94M | $-35.49M | $-33.30M | $-34.93M | $-29.85M | $-24.91M | $-19.08M | $-16.55M | $-11.73M | $-11.34M | $-49.98M | $-7.39M | $-6.09M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -972.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -144060475161987.00% | -16020.19% | -1400.19% | -86.67% |
| EPS | $-0.61 | $-0.64 | $-0.59 | $-0.62 | $-0.63 | $-0.64 | $-0.59 | $-0.48 | $-0.50 | $-0.48 | $-0.71 | $-0.66 | $-0.57 | $-0.48 | $-0.43 | $-0.34 | $-0.59 | $-5.07 | $-0.95 | $-0.81 |
| EPS Diluted | $-0.61 | $-0.64 | $-0.59 | $-0.62 | $-0.63 | $-0.64 | $-0.59 | $-0.48 | $-0.50 | $-0.48 | $-0.71 | $-0.66 | $-0.57 | $-0.48 | $-0.43 | $-0.34 | $-0.59 | $-5.07 | $-0.95 | $-0.81 |
| Weighted Average Shares Outstanding | 110.46M | 110.17M | 99.24M | 94.80M | 86.73M | 86.17M | 74.75M | 70.73M | 70.49M | 69.58M | 49.39M | 45.11M | 43.81M | 39.85M | 38.44M | 34.88M | 19.09M | 9.85M | 7.78M | 7.53M |
| Weighted Average Shares Outstanding Diluted | 110.46M | 110.17M | 99.24M | 94.80M | 86.73M | 86.17M | 74.75M | 70.73M | 70.49M | 69.58M | 49.39M | 45.11M | 43.81M | 39.85M | 38.44M | 34.88M | 19.09M | 9.85M | 7.78M | 7.53M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $98.17M | $53.23M | $139.89M | $219.68M | $242.19M |
| Short Term Investments | $188.91M | $212.48M | $119.39M | $- | $- |
| Cash and Short Term Investments | $287.08M | $265.71M | $259.28M | $219.68M | $242.19M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $9.39M | $5.06M | $5.69M | $5.90M | $5.44M |
| Total Current Assets | $296.47M | $270.77M | $264.97M | $222.63M | $244.91M |
| Property Plant Equipment Net | $26.56M | $30.34M | $31.10M | $4.48M | $4.75M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $7.46M | $- | $1.25M | $1.25M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.86M | $4.86M | $4.75M | $3.73M | $- |
| Total Non-Current Assets | $31.43M | $42.67M | $35.84M | $9.46M | $6.00M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $327.90M | $313.44M | $300.81M | $232.09M | $250.92M |
| Account Payables | $12.01M | $10.65M | $5.84M | $3.48M | $732.00K |
| Short Term Debt | $1.56M | $1.39M | $2.85M | $4.65M | $4.10M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $1.70M | $7.97M | $3.79M |
| Other Current Liabilities | $42.13M | $26.13M | $18.16M | $8.95M | $8.26M |
| Total Current Liabilities | $55.71M | $38.17M | $26.85M | $17.08M | $13.09M |
| Long Term Debt | $15.90M | $17.47M | $18.23M | $831.00K | $3.15M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $15.90M | $17.47M | $18.23M | $831.00K | $3.15M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $71.61M | $55.63M | $45.08M | $17.91M | $16.25M |
| Preferred Stock | $56.52M | $60.03M | $65.83M | $85.40M | $110.88M |
| Common Stock | $110.00K | $86.00K | $70.00K | $44.00K | $32.00K |
| Retained Earnings | $-859.48M | $-603.62M | $-411.21M | $-270.97M | $-198.70M |
| Accumulated Other Comprehensive Income Loss | $447.00K | $246.00K | $-104.00K | $-0 | $- |
| Other Total Stockholders Equity | $1.06B | $801.06M | $601.15M | $399.71M | $322.45M |
| Total Stockholders Equity | $256.29M | $257.80M | $255.74M | $214.18M | $234.67M |
| Total Equity | $256.29M | $257.80M | $255.74M | $214.18M | $234.67M |
| Total Liabilities and Stockholders Equity | $327.90M | $313.44M | $300.81M | $232.09M | $250.92M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $327.90M | $313.44M | $300.81M | $232.09M | $250.92M |
| Total Investments | $188.91M | $219.94M | $119.39M | $1.25M | $1.25M |
| Total Debt | $17.47M | $18.85M | $19.65M | $3.15M | $5.21M |
| Net Debt | $-80.70M | $-34.38M | $-120.24M | $-216.53M | $-236.98M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $98.17M | $97.05M | $88.22M | $215.80M | $53.23M | $86.81M | $214.32M | $160.70M | $139.89M | $140.57M | $325.56M | $191.05M | $219.68M | $202.89M | $218.10M | $230.74M | $242.19M | $129.42M | $21.34M | $29.60M |
| Short Term Investments | $188.91M | $238.47M | $275.00M | $219.94M | $212.48M | $192.23M | $115.08M | $59.57M | $119.39M | $148.53M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $74.85M |
| Cash and Short Term Investments | $287.08M | $335.52M | $363.22M | $435.74M | $265.71M | $312.83M | $350.91M | $220.26M | $259.28M | $289.09M | $325.56M | $191.05M | $219.68M | $202.89M | $218.10M | $230.74M | $242.19M | $129.42M | $21.34M | $29.60M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $9.39M | $6.01M | $6.75M | $6.16M | $5.06M | $6.91M | $5.12M | $10.76M | $5.69M | $7.32M | $5.11M | $7.37M | $5.90M | $9.23M | $6.49M | $2.66M | $5.44M | $6.26M | $5.21M | $1.58M |
| Total Current Assets | $296.47M | $341.53M | $369.97M | $441.90M | $270.77M | $312.83M | $334.52M | $226.27M | $264.97M | $296.42M | $330.68M | $194.73M | $222.63M | $207.50M | $221.35M | $232.07M | $244.91M | $129.42M | $23.95M | $31.18M |
| Property Plant Equipment Net | $26.56M | $27.60M | $28.41M | $29.35M | $30.34M | $30.84M | $31.56M | $32.15M | $31.10M | $30.38M | $30.48M | $5.28M | $4.48M | $4.59M | $3.94M | $4.29M | $4.75M | $5.20M | $5.85M | $6.50M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $10.03M | $26.69M | $- | $7.46M | $33.79M | $21.51M | $- | $- | $- | $- | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.86M | $4.86M | $4.86M | $4.86M | $4.86M | $4.86M | $4.78M | $4.78M | $4.75M | $4.77M | $4.89M | $5.61M | $3.73M | $2.04M | $1.97M | $- | $1.25M | $5.25M | $1.25M | $1.25M |
| Total Non-Current Assets | $31.43M | $42.49M | $59.96M | $34.21M | $42.67M | $69.49M | $57.85M | $36.93M | $35.84M | $35.14M | $35.38M | $12.14M | $9.46M | $7.88M | $7.17M | $5.54M | $6.00M | $10.45M | $7.11M | $7.75M |
| Other Assets | $- | $- | $- | $- | $- | $-26.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $327.90M | $384.02M | $429.94M | $476.11M | $313.44M | $355.45M | $392.37M | $263.20M | $300.81M | $331.56M | $366.05M | $206.87M | $232.09M | $215.38M | $228.52M | $237.61M | $250.92M | $139.87M | $31.05M | $38.94M |
| Account Payables | $12.01M | $15.06M | $8.97M | $15.56M | $10.65M | $9.87M | $7.16M | $4.17M | $5.84M | $4.09M | $3.49M | $4.01M | $3.48M | $4.35M | $1.99M | $315.00K | $732.00K | $639.00K | $632.00K | $628.00K |
| Short Term Debt | $1.56M | $1.52M | $2.95M | $1.43M | $2.77M | $2.69M | $2.35M | $1.89M | $2.85M | $2.01M | $18.11M | $4.79M | $4.65M | $4.51M | $4.37M | $4.23M | $4.10M | $3.98M | $3.40M | $473.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $19.05M | $25.69M | $- | $16.92M | $- | $1.70M | $- | $10.49M | $3.06M | $7.97M | $3.06M | $3.06M | $3.06M | $3.79M | $11.96M | $312.00K | $841.00K |
| Other Current Liabilities | $42.13M | $36.47M | $28.08M | $19.69M | $24.74M | $22.16M | $16.24M | $15.05M | $18.16M | $17.44M | $6.05M | $9.07M | $8.95M | $7.85M | $7.32M | $3.69M | $8.26M | $15.51M | $3.93M | $6.12M |
| Total Current Liabilities | $55.71M | $53.05M | $40.00M | $36.69M | $38.17M | $34.72M | $25.76M | $21.12M | $26.85M | $23.55M | $27.66M | $17.88M | $17.08M | $16.71M | $13.68M | $8.24M | $13.09M | $20.12M | $8.27M | $9.25M |
| Long Term Debt | $15.90M | $16.31M | $16.71M | $17.09M | $17.47M | $17.83M | $18.18M | $18.52M | $18.23M | $18.07M | $19.01M | $1.13M | $831.00K | $1.44M | $2.03M | $2.60M | $3.15M | $3.69M | $3.54M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $15.90M | $16.31M | $16.71M | $17.09M | $17.47M | $17.83M | $18.18M | $18.52M | $18.23M | $18.07M | $19.01M | $1.13M | $831.00K | $1.44M | $2.03M | $2.60M | $3.15M | $3.69M | $3.54M | $3.99M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $138.23M | $- | $- |
| Total Liabilities | $71.61M | $69.36M | $56.71M | $53.78M | $55.63M | $52.55M | $43.94M | $39.63M | $45.08M | $41.62M | $46.67M | $19.01M | $17.91M | $18.15M | $15.71M | $10.85M | $16.25M | $162.04M | $11.81M | $13.24M |
| Preferred Stock | $110.60M | $110.60M | $114.12M | $222.15M | $60.03M | $60.03M | $62.31M | $62.31M | $65.83M | $65.83M | $71.40M | $78.40M | $85.40M | $85.40M | $85.40M | $94.68M | $110.88M | $138.23M | $- | $- |
| Common Stock | $110.00K | $110.00K | $109.00K | $96.00K | $86.00K | $86.00K | $85.00K | $71.00K | $70.00K | $70.00K | $66.00K | $46.00K | $44.00K | $40.00K | $40.00K | $37.00K | $32.00K | $11.00K | $32.00K | $31.00K |
| Retained Earnings | $-859.48M | $-791.56M | $-720.92M | $-661.97M | $-603.62M | $-549.26M | $-493.88M | $-449.80M | $-411.21M | $-371.60M | $-336.53M | $-301.61M | $-270.97M | $-246.06M | $-226.98M | $-210.43M | $-198.70M | $-187.36M | $-137.38M | $-129.99M |
| Accumulated Other Comprehensive Income Loss | $447.00K | $896.00K | $-192.00K | $-39.00K | $246.00K | $-172.00K | $-97.00K | $16.00K | $-104.00K | $-163.00K | $- | $- | $-85.40M | $0 | $-0 | $-0 | $- | $49.13M | $- | $31.76M |
| Other Total Stockholders Equity | $1.00B | $994.61M | $980.11M | $862.10M | $801.06M | $792.21M | $780.01M | $610.97M | $601.15M | $595.80M | $584.45M | $411.02M | $399.71M | $357.86M | $354.34M | $342.47M | $322.45M | $26.95M | $156.59M | $155.66M |
| Total Stockholders Equity | $256.29M | $314.66M | $373.22M | $422.33M | $257.80M | $302.90M | $348.43M | $223.56M | $255.74M | $289.94M | $319.38M | $187.86M | $214.18M | $197.24M | $212.80M | $226.76M | $234.67M | $-22.17M | $19.24M | $25.70M |
| Total Equity | $256.29M | $314.66M | $373.22M | $422.33M | $257.80M | $302.90M | $348.43M | $223.56M | $255.74M | $289.94M | $319.38M | $187.86M | $214.18M | $197.24M | $212.80M | $226.76M | $234.67M | $-22.17M | $19.24M | $25.70M |
| Total Liabilities and Stockholders Equity | $327.90M | $384.02M | $429.94M | $476.11M | $313.44M | $355.45M | $392.37M | $263.20M | $300.81M | $331.56M | $366.05M | $206.87M | $232.09M | $215.38M | $228.52M | $237.61M | $250.92M | $139.87M | $31.05M | $38.94M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $327.90M | $384.02M | $429.94M | $476.11M | $313.44M | $355.45M | $392.37M | $263.20M | $300.81M | $331.56M | $366.05M | $206.87M | $232.09M | $215.38M | $228.52M | $237.61M | $250.92M | $139.87M | $31.05M | $38.94M |
| Total Investments | $188.91M | $248.50M | $301.69M | $219.94M | $219.94M | $226.03M | $136.59M | $59.57M | $119.39M | $148.53M | $- | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $- | $- | $- | $74.85M |
| Total Debt | $17.47M | $17.83M | $18.18M | $18.52M | $18.85M | $19.17M | $19.36M | $19.46M | $19.65M | $20.08M | $28.07M | $3.52M | $3.15M | $3.69M | $4.21M | $4.72M | $5.21M | $5.68M | $5.24M | $5.64M |
| Net Debt | $-80.70M | $-79.22M | $-70.03M | $-197.28M | $-34.38M | $-67.64M | $-194.96M | $-141.24M | $-120.24M | $-120.49M | $-297.50M | $-187.53M | $-216.53M | $-199.20M | $-213.89M | $-226.02M | $-236.98M | $-123.74M | $-16.10M | $-23.96M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $- | $-192.41M | $-140.24M | $-72.27M | $-74.81M |
| Depreciation and Amortization | $- | $3.59M | $5.88M | $147.00K | $720.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-7.49M |
| Stock Based Compensation | $- | $30.62M | $18.37M | $11.69M | $6.02M |
| Change in Working Capital | $- | $11.44M | $751.00K | $2.02M | $-5.32M |
| Accounts Receivables | $- | $- | $- | $- | $2.00M |
| Inventory | $- | $- | $- | $- | $-3.55M |
| Accounts Payables | $1.36M | $4.81M | $2.36M | $2.75M | $-2.45M |
| Other Working Capital | $10.24M | $6.63M | $-1.61M | $-731.00K | $-1.31M |
| Other Non Cash Items | $-207.79M | $-6.87M | $-3.39M | $-343.00K | $45.03M |
| Net Cash Provided by Operating Activities | $-207.79M | $-153.62M | $-118.64M | $-58.76M | $-35.85M |
| Investments in Property Plant and Equipment | $- | $-2.80M | $-6.86M | $-1.72M | $- |
| Acquisitions Net | $- | $- | $117.86K | $- | $8.42M |
| Purchases of Investments | $- | $-348.80M | $-177.85M | $- | $- |
| Sales Maturities of Investments | $- | $253.78M | $60.00M | $- | $- |
| Other Investing Activities | $38.28M | $- | $-117.86K | $- | $8.42K |
| Net Cash Used for Investing Activities | $38.28M | $-97.82M | $-124.72M | $-1.72M | $8.42M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $213.34M | $161.82M | $161.94M | $38.01M | $132.73M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.11M | $1.72M | $1.61M | $-30.00K | $99.47M |
| Net Cash Used Provided by Financing Activities | $214.45M | $163.54M | $163.56M | $37.98M | $232.20M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $44.94M | $-87.91M | $-79.80M | $-22.51M | $204.77M |
| Cash at End of Period | $98.17M | $53.23M | $141.14M | $220.94M | $243.44M |
| Cash at Beginning of Period | $53.23M | $141.14M | $220.94M | $243.44M | $38.68M |
| Operating Cash Flow | $-207.79M | $-153.62M | $-118.64M | $-58.76M | $-35.85M |
| Capital Expenditure | $- | $-2.80M | $-6.86M | $-1.72M | $- |
| Free Cash Flow | $-207.79M | $-156.42M | $-125.50M | $-60.48M | $-35.85M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-67.93M | $-70.63M | $-58.95M | $-58.35M | $-54.37M | $-55.38M | $-44.08M | $-38.59M | $-39.62M | $-35.06M | $-34.93M | $-30.63M | $-24.91M | $-19.08M | $-16.55M | $-11.73M | $-11.34M | $-49.98M | $-7.39M | $-6.09M |
| Depreciation and Amortization | $1.11M | $1.10M | $1.08M | $1.07M | $794.00K | $855.00K | $1.22M | $723.00K | $937.00K | $3.71M | $1.16M | $69.00K | $68.00K | $48.00K | $14.00K | $17.00K | $17.00K | $122.00K | $286.00K | $295.00K |
| Deferred Income Tax | $- | $- | $- | $- | $7.76M | $-7.76M | $- | $- | $- | $- | $- | $- | $-24.70M | $- | $- | $- | $-23.00K | $-7.47M | $- | $- |
| Stock Based Compensation | $9.98M | $10.36M | $10.01M | $9.39M | $8.85M | $8.76M | $7.16M | $5.85M | $5.04M | $4.62M | $4.53M | $4.17M | $3.85M | $3.46M | $2.59M | $1.78M | $866.00K | $3.51M | $870.00K | $769.00K |
| Change in Working Capital | $-1.13M | $13.39M | $2.58M | $-3.24M | $4.94M | $6.89M | $4.37M | $-4.76M | $6.78M | $-6.86M | $2.78M | $-1.94M | $215.00K | $1.46M | $1.43M | $-1.09M | $595.00K | $-1.77M | $-2.09M | $-2.06M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.03M |
| Accounts Payables | $-3.05M | $6.09M | $-6.59M | $4.91M | $787.00K | $2.71M | $2.99M | $-1.67M | $1.75M | $601.00K | $-523.00K | $532.00K | $-866.00K | $2.36M | $1.68M | $-417.00K | $93.00K | $7.00K | $4.00K | $-2.56M |
| Other Working Capital | $1.92M | $7.31M | $9.17M | $-8.15M | $4.16M | $4.18M | $1.38M | $-3.09M | $5.03M | $-7.46M | $3.79M | $-2.48M | $1.08M | $-893.00K | $-243.00K | $-676.00K | $502.00K | $-1.78M | $-2.09M | $-474.00K |
| Other Non Cash Items | $-2.60M | $-6.20M | $2.58M | $5.22M | $-4.29M | $8.67M | $-737.00K | $-2.74M | $-2.54M | $-852.00K | $-523.00K | $3.78M | $24.70M | $1.20M | $941.00K | $-343.00K | $517.00K | $45.32M | $-525.00K | $-808.00K |
| Net Cash Provided by Operating Activities | $-60.58M | $-51.98M | $-42.70M | $-52.53M | $-44.07M | $-37.97M | $-32.07M | $-39.52M | $-29.41M | $-34.44M | $-26.46M | $-28.33M | $-20.78M | $-14.11M | $-12.51M | $-11.37M | $-9.37M | $-10.27M | $-8.32M | $-7.89M |
| Investments in Property Plant and Equipment | $-75.00K | $-280.00K | $-148.00K | $-70.00K | $-315.00K | $-121.00K | $-1.26M | $-1.10M | $-1.97M | $-3.31M | $-1.14M | $-441.00K | $-433.00K | $-1.16M | $-123.00K | $- | $320.00K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $-10.80K | $90.42K | $76.40K | $-60.99K | $-148.23M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-12.72M | $-19.47M | $-150.40M | $-73.01M | $-50.91M | $-112.47M | $-126.40M | $-59.01M | $-29.62M | $-148.23M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $74.47M | $79.93M | $65.92M | $74.13M | $61.72M | $22.06M | $50.00M | $120.00M | $60.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $1.11M | $10.80K | $-90.42K | $-76.40K | $60.99K | $148.23M | $-148.23K | $- | $- | $- | $- | $- | $- | $-320.00K | $8.42M | $- | $- |
| Net Cash Used for Investing Activities | $61.67M | $60.19M | $-84.62M | $1.04M | $10.49M | $-90.54M | $-77.66M | $59.88M | $28.41M | $-151.54M | $-1.14M | $-441.00K | $-433.00K | $-1.16M | $-123.00K | $- | $320.00K | $8.42M | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-109.00K | $-365.00K | $213.70M | $-1.58M | $-170.00K | $161.99M | $445.00K | $315.00K | $-170.00K | $162.12M | $138.00K | $38.01M | $55.00K | $- | $- | $122.06M | $- | $- | $73.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $26.00K | $624.00K | $109.00K | $356.00K | $1.42M | $1.00M | $102.00K | $445.00K | $315.00K | $990.00K | $162.12M | $138.00K | $- | $55.00K | $- | $-85.00K | $77.00K | $109.92M | $62.00K | $- |
| Net Cash Used Provided by Financing Activities | $26.00K | $624.00K | $-256.00K | $214.06M | $- | $1.00M | $162.09M | $445.00K | $315.00K | $990.00K | $162.12M | $138.00K | $38.01M | $55.00K | $- | $-85.00K | $122.14M | $109.92M | $62.00K | $73.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-127.38M | $127.38M | $- | $- | $- | $- | $- | $- | $27.89M | $- | $- | $- | $-320.00K | $- | $- | $- |
| Net Change in Cash | $1.12M | $8.83M | $-127.58M | $162.57M | $-33.58M | $-127.51M | $52.36M | $20.81M | $-682.00K | $-184.99M | $134.51M | $-28.64M | $16.80M | $-15.22M | $-12.63M | $-11.45M | $112.77M | $108.08M | $-8.26M | $-7.82M |
| Cash at End of Period | $98.17M | $97.05M | $88.22M | $215.80M | $53.23M | $86.81M | $214.32M | $161.95M | $141.14M | $141.82M | $326.82M | $192.30M | $220.94M | $204.14M | $219.36M | $231.99M | $243.44M | $130.68M | $22.60M | $30.86M |
| Cash at Beginning of Period | $97.05M | $88.22M | $215.80M | $53.23M | $86.81M | $214.32M | $161.95M | $141.14M | $141.82M | $326.82M | $192.30M | $220.94M | $204.14M | $219.36M | $231.99M | $243.44M | $130.68M | $22.60M | $30.86M | $38.68M |
| Operating Cash Flow | $-60.58M | $-51.98M | $-42.70M | $-52.53M | $-44.07M | $-37.97M | $-32.07M | $-39.52M | $-29.41M | $-34.44M | $-26.46M | $-28.33M | $-20.78M | $-14.11M | $-12.51M | $-11.37M | $-9.37M | $-10.27M | $-8.32M | $-7.89M |
| Capital Expenditure | $-75.00K | $-280.00K | $-148.00K | $-70.00K | $-315.00K | $-121.00K | $-1.26M | $-1.10M | $-1.97M | $-3.31M | $-1.14M | $-441.00K | $-433.00K | $-1.16M | $-123.00K | $- | $320.00K | $- | $- | $- |
| Free Cash Flow | $-60.65M | $-52.26M | $-42.85M | $-52.60M | $-44.38M | $-38.09M | $-33.32M | $-40.62M | $-31.38M | $-37.75M | $-27.60M | $-28.77M | $-21.21M | $-15.27M | $-12.63M | $-11.37M | $-9.05M | $-10.27M | $-8.32M | $-7.89M |
Cogent Biosciences Dividends
Explore Cogent Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Cogent Biosciences News
Read the latest news about Cogent Biosciences, including recent articles, headlines, and updates.
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025.
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap.
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass.
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors (GIST). The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1. Cogent also announced today a new Phase 2 clinical trial of bezuclastinib plus sunitinib in later line GIST patients, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) on behalf of the company's shareholders. The investigation seeks to determine whether Cogent Biosciences, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on:
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2024 milestones ahead of its presentation at J.P. Morgan's 42nd annual healthcare conference.
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 4:30 p.m. PT/7:30 p.m. ET.
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine potential competitors, in analysts' view. In a trial of bezuclastinib in patients with nonadvanced systemic mastocytosis, a rare blood disorder in which too many mast cells build up in the body, everyone treated with the therapy achieved at least 50% improvement in all relevant biomarker measures, Cogent said Friday at the American Society of Hematology annual meeting in San Diego.
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry B. González Convention Center in San Antonio, Texas.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for COGT.